July 8th 2025
The FDA accepted Eton Pharmaceuticals' NDA for ET-600 for pediatric arginine vasopressin deficiency, with a target action date in February of 2026.
Glucose levels are in target range at higher percentage with hybrid closed-loop system
May 16th 2023A hybrid closed-loop system can deliver glucose levels in the target range at a higher percentage of time among children aged 2 years to younger than 6 years compared to standard-care, according to a study in the New England Journal of Medicine.
Equitable access to glucose monitoring improves HbA1c levels
May 8th 2023Hemoglobin A1c improved in youths with newly diagnosed type 1 diabetes (T1D) when inclusive continuous glucose monitoring (CGM) was initiated, irrespective of ethnicity or insurance status. According to a study published in Jama Network Open, universal CGM could play a role in reducing disparities for minoritized racial and ethnic groups.
How insulin changed the way type 1 diabetes was treated in children
April 14th 2023Andrew Lam, MD, retinal surgeon, author, assistant professor, University of Massachusetts Medical School discusses the earliest treatments for type 1 diabetes in children, a topic of his new book, "The Masters of Medicine: Our Greatest Triumphs in the Race to Cure Humanity’s Deadliest Diseases," due out April 18, 2023.
FDA approves teplizumab for delay of type 1 diabetes in patients 8 years and up
November 18th 2022The US FDA announced the approval of teplizumab (Tzield), which is administered through IV infusion once daily for 14 consecutive days, for delaying the onset of stage 3 type 1 diabetes in adults and pediatric patients 8 years and older who currently have stage 2 type 1 diabetes.